Adcendo ApS is a biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need.
The company is advancing a clinical ADC pipeline including programs ADCE-T02 (Tissue Factor), ADCE-D01 (uPARAP), and ADCE-B05, focusing on dose escalation and expansion studies across multiple tumor indications.
Leadership & Board
Current Number of Employees67
Current LinkedIn Followers11,204
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$75M
Total Amount Raised$75M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$75M
Latest Funding Amount$75M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Adcendo ApS had 67 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
67Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Adcendo ApS had 11,204 followers as of September 14, 2026. The number of followers increased by 35 (0.31%) week-over-week.
11,204Latest Followers Count
35(0.31%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.